Dr Morse is a regular and invaluable contributor to Expert Opinion on Biological Therapy, having joined the Editorial Board in 2000 and accepting the position of Editor-in-Chief in 2007. He is currently Associate Professor of Medicine at Duke University, and is a G.I. Oncologist at Duke Comprehensive Cancer Center, where his clinical expertise lies in the treatment of gastrointestinal and hepatic malignancies, and malignant melanoma.Dr Morse’s research focuses on developing strategies to activate T cell responses against tumors by immunizing patients with dendritic cell based vaccines. His group has continued to develop modifications to these vaccines, including loading with antigen in the form of peptides, mRNA, viral vectors and maturing dendritic cells with cytokines. Most recently, they have focused on genetically altering the expression of co-stimulatory and adhesion molecules, and have also identified preliminary data which suggests that it may be important to activate antibody responses as well as T cells in order to initiate immune-mediated destruction of tumors. The group is also working on other methods of modulating immune response, including anti-CTLA4 antibodies and strategies that interfere with inhibitory molecules such as PDL1. Further areas of research include other anti-cancer therapies to weaken the tumor’s ability to impair immune response, including combinations of cancer vaccines along with chemotherapy, radiotherapy, and targeted therapies.
Dr Morse has contributed many papers to Expert Opinion on Biological Therapy during his time on the Editorial Board, including his recent papers listed below:
Countering tumor-induced immunosupression during immunotherapy for pancreatic cancer
Michael A Morse Joseph Robert Hall, Janet MD Plate
Expert Opinion on Biological Therapy, Mar 2009, Vol. 9, No. 3, Pages 331-339.
Update on anti-CTLA-4 antibodies in clinical trials
Lee F Langer, Timothy M Clay, Michael A Morse
Expert Opinion on Biological Therapy, Aug 2007, Vol. 7, No. 8, Pages 1245-1256.
Vascular endothelial growth factor and immunosupression in cancer: current knowledge and potential for new therapy
Benjamin F Johnson, Timothy M Clay, Amy C Hobeika, H Kim Lyerly, Michael A Morse
Expert Opinion on Biological Therapy, Apr 2007, Vol. 7, No. 4, Pages 449-460.
No comments:
Post a Comment